Affimed (AFMD) Shares Up 6.6%

Affimed NV (NASDAQ:AFMD) shares shot up 6.6% on Thursday . The company traded as high as $4.32 and last traded at $4.22. 1,578,713 shares were traded during trading, an increase of 45% from the average session volume of 1,088,334 shares. The stock had previously closed at $3.96.

A number of brokerages have recently weighed in on AFMD. Zacks Investment Research downgraded Affimed from a “buy” rating to a “hold” rating in a report on Friday. BidaskClub upgraded Affimed from a “strong sell” rating to a “sell” rating in a report on Saturday, November 3rd. ValuEngine upgraded Affimed from a “hold” rating to a “buy” rating in a report on Thursday, November 1st. SunTrust Banks lowered their price target on Affimed to $5.00 and set a “buy” rating on the stock in a report on Thursday, October 11th. Finally, BMO Capital Markets lifted their price target on Affimed from $4.00 to $5.00 and gave the company an “outperform” rating in a report on Tuesday, August 28th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $4.81.

The company has a quick ratio of 5.33, a current ratio of 5.36 and a debt-to-equity ratio of 0.06. The firm has a market cap of $247.07 million, a price-to-earnings ratio of -5.21 and a beta of 3.62.

Affimed (NASDAQ:AFMD) last issued its earnings results on Wednesday, November 7th. The biopharmaceutical company reported ($0.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.05). Affimed had a negative net margin of 2,124.72% and a negative return on equity of 77.87%. The firm had revenue of $0.36 million during the quarter, compared to analysts’ expectations of $0.30 million. Sell-side analysts expect that Affimed NV will post -0.64 earnings per share for the current fiscal year.

Hedge funds and other institutional investors have recently modified their holdings of the business. Canada Pension Plan Investment Board purchased a new position in Affimed in the second quarter valued at about $165,000. Dimensional Fund Advisors LP grew its stake in Affimed by 28.8% in the first quarter. Dimensional Fund Advisors LP now owns 319,871 shares of the biopharmaceutical company’s stock valued at $592,000 after purchasing an additional 71,545 shares in the last quarter. Millennium Management LLC purchased a new position in Affimed in the first quarter valued at about $4,731,000. Stanley Laman Group Ltd. purchased a new position in Affimed in the second quarter valued at about $100,000. Finally, Renaissance Technologies LLC grew its stake in Affimed by 38.8% in the second quarter. Renaissance Technologies LLC now owns 177,510 shares of the biopharmaceutical company’s stock valued at $293,000 after purchasing an additional 49,610 shares in the last quarter. Hedge funds and other institutional investors own 40.62% of the company’s stock.

WARNING: This news story was posted by WKRB News and is the property of of WKRB News. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark and copyright legislation. The original version of this news story can be read at https://www.wkrb13.com/2018/11/10/affimed-afmd-shares-up-6-6.html.

Affimed Company Profile (NASDAQ:AFMD)

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead candidate is AFM13, a natural killer cell (NK-cell) TandAb, which is in Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed Hodgkin lymphoma.

See Also: Average Daily Trade Volume – What It Means In Stock Trading

Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply